Smithy JW, Kalvin HL, Ehrich FD, Shah R, et al. Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study. Clin Cancer Res 2024;30:3407-3415.
PMID: 38767650